Regeneron Pharmaceuticals, Inc. (REGN) reported a 36% jump in earnings for the first quarter of 2020 helped by higher revenue. The results exceeded analysts’ expectations.
The company is advancing REGN-COV2, a novel investigational antibody “cocktail” treatment designed to prevent and treat the SARS-CoV-2 (COVID-19) virus. The company is working to rapidly scale-up manufacturing, with a goal to have hundreds of thousands of preventative doses available by the end of August 2020.
Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications.
A visual representation of Regeneron's earnings can be found here
The company is advancing REGN-COV2, a novel investigational antibody “cocktail” treatment designed to prevent and treat the SARS-CoV-2 (COVID-19) virus. The company is working to rapidly scale-up manufacturing, with a goal to have hundreds of thousands of preventative doses available by the end of August 2020.
Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications.
A visual representation of Regeneron's earnings can be found here